Lung Cancer

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

A lung and breast cancer survivor shares how genetic history, supporting her daughter and leading a support group helped her keep smiling.

A SEER-Medicare study found nearly half of older patients with metastatic non–small cell lung cancer never received systemic therapy.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

Gotistobart reduced risk of death by 54% and doubled 12-month survival vs chemotherapy in advanced squamous NSCLC after prior treatment.

Libtayo improved survival and safety outcomes vs chemotherapy in advanced NSCLC, with 23% of patients alive at six years in the EMPOWER-Lung 1 trial.

Nuvalent submitted an NDA for neladalkib to the FDA for patients with previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 trial data showing activity.

New research shows adults over 80 with early-stage lung cancer can achieve surgical outcomes and quality of life comparable to younger patients.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone.

KRAS G12d-targeted protein degrader setidegrasib demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12d-mutant non–small cell lung cancer.

Zegfrovy helped patients live longer without cancer growth and improved tumor response compared with chemotherapy in first-line lung cancer treatment.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and survivorship lung health.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

Looking back over the setbacks and blessings of the roller coaster ride that was my cancer treatment journey.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.